Literature DB >> 4557308

Clinical trial of a new carbenoxolone analogue (BX24), zinc sulphate, and vitamin A in the treatment of gastric ulcer.

P M Fraser, R Doll, M J Langman, J J Misiewicz, H H Shawdon.   

Abstract

The effects of a new carbenoxolone analogue (BX24), zinc sulphate, and vitamin A on the healing of gastric ulcer have been assessed in a multifactorial clinical trial conducted in out-patients treated for four weeks.Forty-eight patients completed the trial. Three groups of eight patients were given respectively 300, 600, and 1 200 mg of BX24 daily and were compared with 24 patients who were given 300 mg of carbenoxolone sodium daily. The size of the ulcer niche was reduced on average by 14.6% in the eight patients given BX24 300 mg daily, by 47.6% in the patients given 600 mg daily, and by 51.0% in the patients given 1 200 mg daily. In the patients given carbenoxolone the size of the niche was reduced by 68.9%. These results were compared with those obtained previously with carbenoxolone and inert tablets and it was concluded that BX24 is without clinically useful effect in the doses used. Eleven of the 24 patients (46%) treated with carbenoxolone sodium developed side effects due to fluid retention and electrolyte disturbances. None of the patients given BX24 experienced such effects. In addition to carbenoxolone or BX24, 24 patients were given zinc sulphate, 660 mg daily, and in 24 patients these tablets were withheld. Among the patients given carbenoxolone the reduction in the size of the niche was much the same irrespective of whether or not the patients received zinc sulphate. Among the 12 patients given BX24 with zinc sulphate the ulcer healed completely in four and, on average, the size of the niche was reduced by 53.5%, compared with 21.9% in the 12 patients given BX24 alone. This difference is not statistically significant but the possibility of a beneficial effect from zinc is not excluded. No side effects attributable to zinc were observed.Twenty-four patients were also given vitamin A, 50 000 units daily, and in 24 patients the vitamin was withheld. No evidence was obtained to suggest that vitamin A had any beneficial effect on the healing of gastric ulcer.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4557308      PMCID: PMC1412200          DOI: 10.1136/gut.13.6.459

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  8 in total

1.  MEDICAL TREATMENT OF GASTRIC ULCER.

Authors:  R DOLL
Journal:  Scott Med J       Date:  1964-05       Impact factor: 0.729

2.  TREATMENT OF GASTRIC ULCER WITH CARBENOXOLONE SODIUM AND OESTROGENS.

Authors:  R DOLL; I D HILL; C F HUTTON
Journal:  Gut       Date:  1965-02       Impact factor: 23.059

3.  Radiozinc studies in experimental wound healing.

Authors:  E D SAVLOV; W H STRAIN; F HUEGIN
Journal:  J Surg Res       Date:  1962-05       Impact factor: 2.192

4.  Acceleration of wound healing in man with zinc sulphate given by mouth.

Authors:  W J Pories; J H Henzel; C G Rob; W H Strain
Journal:  Lancet       Date:  1967-01-21       Impact factor: 79.321

5.  Oral zinc sulphate in leg ulcers.

Authors:  S L Husain
Journal:  Lancet       Date:  1969-05-31       Impact factor: 79.321

6.  Treatment of gastric ulcer with carbenoxolone: antagonistic effect of spironolactone.

Authors:  R Doll; M J Langman; H H Shawdon
Journal:  Gut       Date:  1968-02       Impact factor: 23.059

7.  Oral zinc sulphate in sickle-cell ulcers.

Authors:  G R Serjeant; R E Galloway; M C Gueri
Journal:  Lancet       Date:  1970-10-31       Impact factor: 79.321

8.  Effects of long-continued ingestion of zinc sulphate in patients with venous leg ulceration.

Authors:  M W Greaves; A W Skillen
Journal:  Lancet       Date:  1970-10-31       Impact factor: 79.321

  8 in total
  21 in total

Review 1.  Drugs in the treatment of gastric and duodenal ulcer.

Authors:  M J Langman
Journal:  Drugs       Date:  1977-08       Impact factor: 9.546

2.  Management of chronic peptic ulcer and its complications.

Authors:  D W Piper; V H Cumberland; D I Fevre
Journal:  Drugs       Date:  1975       Impact factor: 9.546

Review 3.  Some aspects of medical management of gastrointestinal disease. I.

Authors:  B W Badley
Journal:  Can Med Assoc J       Date:  1975-01-25       Impact factor: 8.262

Review 4.  Vascular remodeling and mineralocorticoids.

Authors:  K T Weber; Y Sun; S E Campbell; S H Slight; V K Ganjam
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

5.  Carbenoxolone sodium: its role in ulcer healing.

Authors:  M J Langman
Journal:  Drugs       Date:  1976       Impact factor: 9.546

6.  Zinc in ulcerative colitis: a therapeutic trial and report on plasma levels.

Authors:  M W Dronfield; J D Malone; M J Langman
Journal:  Gut       Date:  1977-01       Impact factor: 23.059

7.  Does increased gastric mucus play a role in the ulcer-protecting effects of zinc sulphate?

Authors:  C H Cho; C W Ogle
Journal:  Experientia       Date:  1978-01-15

8.  Medical treatment of gastric and duodenal ulcer.

Authors:  J H Baron
Journal:  Klin Wochenschr       Date:  1976-10-01

Review 9.  Carbenoxolone: a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease.

Authors:  R M Pinder; R N Brogden; P R Sawyer; T M Speight; R Spencer; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

10.  Effects of zinc L-carnosine on gastric mucosal and cell damage caused by ethanol in rats. Correlation with endogenous prostaglandin E2.

Authors:  T Arakawa; H Satoh; A Nakamura; H Nebiki; T Fukuda; H Sakuma; H Nakamura; M Ishikawa; M Seiki; K Kobayashi
Journal:  Dig Dis Sci       Date:  1990-05       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.